Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T Cell Treatment for Relapsed/Refractory Large B Cell Lymphoma or Grade IIIB Follicular Lymphoma
NCT Number:
NCT05633615
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Non-Hodgkin's Lymphoma
Study Objectives:
To compare the progression-free survival in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (PR) on first imaging response by central review (day +30 PET/CT scan) after commercial CD19 CAR T-cell therapy who are randomized to receive each consolidation therapy versus those that receive no consolidation therapy (i.e. control). Specifically, to compare the PFS of 1) mosunetuzumab consolidation to no consolidation, 2) polatuzumab vedotin consolidation to no consolidation, 3) mosunetuzumab + polatuzumab vedotin to no consolidation
Study Documents
(MUSC NetID required for document access)